Julia Xiong

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · Journal of Clinical Oncology · 2022 · 235 citations

Medicine, Oncology, Pharmacology +17

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial

David M. Loeb, Ji Won Lee, Daniel A. Morgenstern et al. · Cancer Immunology Immunotherapy · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development

Federico Innocenti, Jacqueline Ramı́rez, Jennifer Obel et al. · Pharmacogenetics and Genomics · 2013 · 15 citations

Medicine, Pharmacokinetics, Pharmacology +14

Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Howard A. Burris, Takuji Okusaka, Arndt Vogel et al. · Journal of Clinical Oncology · 2022 · 15 citations

Medicine, Oncology, Pharmacology +11

Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).

Arndt Vogel, Li‐Tzong Chen, Aiwu Ruth He et al. · Journal of Clinical Oncology · 2022 · 12 citations

Medicine, Oncology, Pharmacology +10